Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Change in Accured Expenses (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 4 years of Change in Accured Expenses data on record, last reported at -$2.0 million in Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 83.54% year-over-year to -$2.0 million; the TTM value through Sep 2025 reached -$19.1 million, down 278.14%, while the annual FY2024 figure was -$18.0 million, 265.05% down from the prior year.
  • Change in Accured Expenses reached -$2.0 million in Q3 2025 per ZNTL's latest filing, up from -$10.6 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $11.8 million in Q2 2024 and bottomed at -$15.2 million in Q1 2024.
  • Average Change in Accured Expenses over 4 years is -$543933.3, with a median of -$1.4 million recorded in 2023.
  • The widest YoY moves for Change in Accured Expenses: up 368.48% in 2024, down 980.72% in 2024.
  • A 4-year view of Change in Accured Expenses shows it stood at $5.0 million in 2022, then skyrocketed by 105.88% to $10.4 million in 2023, then plummeted by 124.64% to -$2.6 million in 2024, then rose by 22.87% to -$2.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were -$2.0 million in Q3 2025, -$10.6 million in Q2 2025, and -$4.0 million in Q1 2025.